ADA Releases 2020 Standards of Medical Care in Diabetes
The American Diabetes Association (ADA) has released the 2020 Standards of Medical Care in Diabetes. The resource includes all of the ADA's current clinical practice recommendations, intended to provide clinicians, patients, researchers, payers, and others with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care.
FDA Approves Use of Vascepa To Reduce Cardiovascular Events
Earlier this month, the U.S. Food and Drug Administration approved the use of Vascepa (icosapent ethyl) as secondary therapy among adults with elevated triglyceride levels. Vascepa is now the first FDA approved drug to be used in addition to statin therapy to reduce cardiovascular risk among patients with elevated triglyceride levels with an established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease.
Cohort Study Finds Association Between Ultra-Processed Foods and T2D
An observational prospective study of 104,707 participants sought to determine whether the consumption of ultra-processed foods (UPF) is associated with increased risk of type to diabetes (T2D). Published in JAMA Internal Medicine, the research found that the "absolute amount of UPF consumption (grams per day) was consistently associated with T2D risk, even when adjusting for unprocessed or minimally processed food intake."
DAPA-HF Trial Finds the Dapagliflozin Reduced Risk Across A Broad Spectrum of Age
The Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial has demonstrated that dapagliflozin (a sodium-glucose cotransporter 2 [SGLT2] inhibitor) is superior to placebo among patients with heart failure with reduced ejection fraction (HFrEF) in reducing the primary outcome of cardiovascular death or hospitalization for heart failure. Further, the trial found that the benefits were consistent across the age spectrum in diabetics/nondiabetics. The study's authors noted that "Dapagliflozin may signal a new approach in the treatment of patients with HFrEF."
In light of recent cardiovascular trials, a significant amount of conversation has emerged regarding the extent to which cardiologists and other clinicians should be involved in diabetes management. Who is ultimately responsible for applying this evidence into practice? Let us know your thoughts in this brief survey.
A recent studypublished in Clinical Gastroenterology and Hepatology outlines the effects of chronic intestinal inflammation common in Crohn’s disease and ulcerative colitis on glucose levels, and its contribution to increased T2D risk.
Meet Dr. Clyde W. Yancy, MD, MSc, MACP, the Chief Cardiologist at Northwestern Memorial Hospital, and the Magerstadt Professor of Medicine at Northwestern University Feinberg School of Medicine. Among many roles, Dr. Yancy has served as President of the American Heart Association, and is a member of the ACC Guidelines Taskforce which oversees all ACC/AHA guidelines.
